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Objective: We began minimally invasive mitral valve surgery in August, 1996, to
reduce hospital costs, to improve patient recovery, cosmetic appearance, and to
decrease trauma, yet maintain the same quality of surgery. To validate this approach
we reviewed our entire experience through May 2002.
Methods: From August 1996 to May 2002, we performed 413 minimally invasive
mitral valve operations including 51 mitral valve replacements and 362 mitral valve
repairs. Excluding 4 robotically assisted repairs, we evaluated 358 patients, using the
mitral valve repairs as the basis for this retrospective survey. These operations were
performed through a 6- to 8-cm minimally invasive incision, beginning with parasternal
and, most recently, lower ministernotomy (181 patients). The mitral valve reparative
techniques include repair of 94 prolapsed anterior leaflets, posterior leaflet resection,
leaflet advancement, commissuroplasty, Polytetrafluoroethylene (PTFE; Gore-Tex,
W. L. Gore & Associates, Inc, Flagstaff, Ariz) chordal placement, and ring annuloplasty.
Cannulation sites varied but primarily utilized a miniaturized system of 24F catheters in
both the inferior and superior venae cavae with assisted venous suction. The Cosgrove
ring was used in 95% of the patients undergoing this procedure.
Results: The operative mortality was 0/358. Perioperative morbidity included a 26%
incidence of new atrial fibrillation, 2% incidence of pacemaker implantation, 0.5%
incidence of deep sternal wound infection, and 1.9% incidence of stroke after an
operation. There were 10 arterial and 3 venous complications. The mean length of
stay was 6 days and 208 patients stayed 5 days. Only 25% of the patients
underwent homologous blood transfusion. The mean follow-up was 36 months with
1.4% lost to follow-up. There were 12 late deaths and a survival at 5 years of 95%.
There were 21 valves requiring reoperation for structural valve failure of 5.8%. The
probability of freedom from reoperation at 5 years was 92%.
Conclusion: This study documents the safety of minimally invasive mitral valve
repair surgery in 358 patients. It also documents a low incidence of homologous
blood use, requirement for post–hospital rehabilitation, and general morbidity.
To decrease trauma, reduce cost, and speed patient recovery, yetmaintain the same quality of surgery, we began minimally invasivemitral valve surgery in 1996.1 This approach has been performed inpatients who have isolated mitral valve disease without concomitantcoronary artery disease. We retrospectively reviewed our entireconsecutive experience of minimally invasive mitral valve repairs to
determine the long-term survival and reoperation for valve failure.
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From August 1, 1996, to May 1, 2002, 413 patients underwent
minimally invasive mitral valve surgery. Fifty-one patients (12%)
had a mitral valve replacement and 362 (88%) had mitral valve
repair. During the same period, a total of 526 patients underwent
isolated mitral valve repair; thus the 362 minimally invasive pa-
tients represent 69% of mitral valve repair operations at our
institution during that time. Four patients had a robotically assisted
repair and are excluded, leaving 358 patients for review.
Patient demographics are shown in Table 1. The mean age was
57 years, 60% were men, and the mean functional class was 2.2 
2.6. The mean left ventricular ejection fraction was 59%  11%,
and pulmonary hypertension established by right heart catheter-
ization or echocardiography was found in 124 (35%) of patients.
Mitral valve pathophysiology was predominantly regurgitant in
350 (98%) and mixed stenotic and regurgitant in 8 patients (2%).
Most patients had myxomatous degenerated, prolapsed valves,
which accounted for approximately 90% of the valve diseases,
although a small group had a variety of other conditions including
rheumatic disease, endocarditis, ischemia, and congenital and di-
lated cardiomyopathy. Preoperative chronic atrial fibrillation was
found in 102 (28%) of patients. Single vessel coronary disease was
present in 5 patients. All patients were reviewed from January to
May 2002 either by clinical examination or by telephone interview
with the patient or the patient’s local physician.
Surgical Technique
Table 2 lists the surgical approaches that have evolved over the 6
years of this study. Our first approach, beginning in August 1996,
was a right parasternal incision, which was performed in 168
patients. This approach was abandoned approximately 3 years ago
for cosmetic reasons. A right thoracotomy has been performed in
9 patients. The incision currently used is a 6- to 8-cm lower
ministernotomy, which was performed in 181 patients. The tech-
nique of choice for exposure of the mitral valve was the right atrial
transseptal approach performed in 283 patients (78%) with the left
atrial incision used in 79 patients. Over the past 12 months the left
atrial approach has become the exposure of choice because of
improved instruments to expose the valve through the left atrial
incision.
Initially, some patients underwent peripheral cannulation to
minimize cannulas in the chest to improve exposure, particularly in
deep-chested individuals. Table 2 indicates the site of arterial
cannulation for cardiopulmonary bypass, which includes 128 fem-
oral artery cannulations and 230 in the ascending aorta. Percuta-
neous inferior vena cava (IVC) cannulation via the femoral vein
was used in 224 patients. Of those, 16 patients underwent both
percutaneous femoral vein and jugular vein cannulation for IVC
and superior vena cava (SVC) cannulation, respectively, thus
keeping both atrial cannulas out of the incision. Peripheral venous
cannulation is transesophageal, using a guide wire. In addition, the
use of miniaturized techniques for cardiopulmonary bypass has
further improved exposure, particularly with peripheral venous







Mean NYHA functional class 2.2 0.6
Mean ejection fraction (%) 59 11









Anterior leaflet prolapse 23 6%
Bileaflet prolapse 71 20%





Dilatative cardiomyopathy 7 2%
Calcific/degenerative 3 1%
Other 3 1%
Preoperative atrial fibrillation 102 28%
Coronary artery disease
None 353 98.6%




NYHA, New York Heart Association functional classification; PAP, pulmo-
nary artery pressure; PTCA, percutaneous transluminal coronary angio-
plasty; CABG, coronary artery bypass grafting.
*Numbers indicate multiple abnormalities in a single patient.
TABLE 2. Surgical technique: Incision and cardiopulmo-
nary bypass (N  358)
Incision
Lower ministerntotomy 181 50%
Right parasternal 168 46.4%
Right thoracotomy 9 2.5%
Surgical approach
Left atrium 75 21.3%




Femoral artery 128 36%
Venous cannulation
Right atrium–bicaval 134 37%
Femoral vein/SVC or IVC 224 62%
Cardioplegia
Antegrade only 309 87%
Antegrade and retrograde 49 13%
Operative duration (min)
Mean aortic crossclamp 86 30
Mean CPB 128 40
CPB, Cardiopulmonary bypass; SVC, superior vena cava; IVC, inferior vena
cava.
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cannulation using 16F to 24F cannulas with the aid of assisted
venous suction.2 The femoral artery has been cannulated by the
Seldinger technique without incising the artery.
We have adopted our current technique of lower ministerno-
tomy (Figure 1), based on the work by Doty and coworkers,3 who
have used this incision for a variety of cardiac operations. Cardio-
plegia was used in all patients; 309 had antegrade and 49 patients
had both antegrade and retrograde routes used. Intracardiac air was
actively removed by cardiac filling and active aortic root suction.
Air removal was monitored by transesophageal echocardiography
in all patients.
Table 3 outlines the mitral valve reparative techniques. The
majority of patients had a posterior leaflet resection and sliding
valvuloplasty with placement of an annuloplasty ring. A consid-
erable number of patients underwent reduction of prolapse of the
anterior leaflet of the mitral valve, including 94 patients who had
anterior leaflet resection, chordal plasty, or commissuroplasty. The
most frequently inserted ring annuloplasty device was the Cos-
grove-Edwards ring (Edwards Lifesciences, Irvine, Calif) with a
smaller number using a Carpentier-Edwards ring (Edwards Life-
sciences). In 20 patients no ring was used because of no perceived
annular dilatation, production of severe systolic anterior motion, or
concern about recent acute endocarditis.
Intraoperative mitral regurgitation (MR) was estimated by
transesophageal echocardiography in all patients at the time of the
operation (Figure 2). Preoperatively, all patients had 3 to 4MR.
Postoperatively, echocardiography showed the vast majority had 0
to 1MR. Twenty-four patients had concomitant procedures in-
cluding closure of atrial septal defects, tricuspid valve repairs, and
a coronary artery bypass graft to the right coronary artery in one
patient.
Results
Early and late results were tabulated by the Brigham Car-
diac Valve Center database. Operative and perioperative
Figure 1. A, Lower ministernotomy incision. B, Cardiopulmonary bypass perfusion setup for ministernotomy
approach to the mitral valve. C, Transseptal exposure of the mitral valve.
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complications were calculated, as well as late follow-up,
including survival and freedom from thromboembolism,
endocarditis, valve failure, and reoperation. Statistical data
are expressed as percent or mean  1 SD. Survival and
time-related event analysis was performed by the Kaplan-
Meier method. The statistical package used was Stata 6.0
for Windows (Stata Corporation, College Station, Tex). The
operative results are shown in Table 4. There were no
operative deaths (30 days or same hospital admission) in
358 patients. During the same period in the minimally
invasive mitral valve replacement series, there was 1 death
in the 51 procedures, that of a 91-year-old woman. New-
onset atrial fibrillation occurred in 69 patients or 26% of
those patients who were admitted in sinus rhythm. Place-
ment of a permanent pacemaker for conjunctional rhythm or
complete heart block occurred in 6 patients (1.7%) and a
myocardial infarction occurred in 2 patients (0.5%). Anti-
coagulation with warfarin sodium (Coumadin) was given
only to patients with atrial fibrillation postoperatively, either
chronic or new onset. At 6 weeks, if the patient was in
normal sinus rhythm, anticoagulation was discontinued.
There were no major anticoagulation hematologic compli-
cations.
Peripheral vascular complications are listed in Table 4.
There were 3 patients with deep venous thromboses
(0.82%), and 5 of 128 patients who had a femoral artery
cannulation for bypass had a complication requiring an
TABLE 3. Surgical technique (N  358)
Mitral valve repair*





Anterior leaflet resection 5 1%
Cleft closure 13 3%
Decalcification 11 3%
Imbrication suture 15 4%
Compression suture 1 0.3%
Alfieri stitch 27 7%
Annuloplasty only 15 4%
Valve debridement 3 1%
Ring annuloplasty




Carpentier-Edwards Physio ring 12 3%
None 20 5.5%




TVP and ASD 1 0.3%
Aortic valve repair 1 0.3%
Ascending aorta repair 2 0.5%
Carotid endarterectomy 1 0.2%
Coronary artery bypass graft 1 0.2%
ASD, Atrial septal defect; TVP, tricuspid valve annuloplasty.
*Multiple procedures were performed in a single patient.
Figure 2. A, Intraoperative prerepair mitral regurgitation by TEE.
B, Intraoperative post-repair mitral regurgitation by transesoph-
ageal echocardiography.
TABLE 4. Perioperative mortality and morbidity (N  358)
Operatie mortality 0 0
Cardiac complications
New atrial fibrillation 68/260 26%
Permanent pacemaker 6 1.6%
IABP required 1 0.3%





Pleural effusion drained 4 1.1%
Reoperation for bleeding 9 2.5%
CVA documented by CT 7 1.9%
Wound complications
Dehiscence 2 0.6%
Superficial wound infection 3 0.8%
Deep sternal wound infection 2 0.6%
Vascular complications
Femoral vessel injury 5 1.4%
Pseudoaneurysm 2 0.6%
Ascending aortic dissection 3 1.5%
DVT/PE 3 0.8%




Transfer to rehabilitation center 29 8%
Homologous blood transfusion
None 269 75%
1 unit 89 25%
IABP, Intra-aortic balloon pump; CVA, cerebrovascular accident; CT, com-
puted tomography; DVT, deep vein thrombosis; PE, pulmonary embolism.
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additional procedure (3.9%). Three patients sustained a lo-
cal ascending aortic dissection as a result of a cardioplegia
needle placement diagnosed by transesophageal echocardio-
gram, requiring resection and grafting of the ascending
aorta, all done through the same incision. Perioperative
neurologic complications documented by computed tomo-
graphic scan showing a central defect occurred in 7 patients
(2%). Nine patients (2.5%) were reoperated on for periop-
erative bleeding and 10 patients (2.8%) had a pleural or
pericardial effusion requiring postoperative drainage after
hospital discharge. Wound complications were low, with a
deep wound infection in 2 patients (0.5%), superficial
wound infections in 3 requiring antibiotics only, and a
dehiscence of a right parasternal incision necessitating re-
operation in 2 patients. The mean hospital stay was 6.2 days,
with 208 patients having a stay of 4 hospital days. Ho-
mologous red blood cells were transfused in 90 patients
(25%), although only 8% of the patients (28/358) were
transferred to rehabilitation facilities after hospital dis-
charge.
Long-term Follow-up
Duration of follow-up ranged from 0.6 to 69 months with a
mean of 36  19 months. Five patients (1.4%) who live in
foreign countries were lost to follow-up. The mean New
York Heart Association functional class at follow-up was
1.2  0.5 in 98% of the 353 patients available for evalua-
tion. Late complications are summarized in Table 5. The
survival curve shown in Figure 3 indicates a survival at 5
years of 95%. The causes of late death in 12 patients were
cardiac in 6 and other causes, such as cancer and accident,
in the remaining 6.
Reoperation for structural valve failure occurred in 21 of
the 358 patients (5.8%). The probability of freedom from
reoperation is shown in Figure 4 and is 92% at 5 years.
Twelve valve failures occurred in the first half of the series
and 9 in the second half. On review of our results we found
that valve repair failures fell into 4 categories. Six of 21
occurred due to failure of anterior leaflet repair. Anterior
leaflet repair was done in 94 patients, so that 7% of those
who had operations on the anterior leaflet either alone or
because of bileaflet prolapse had a failed repair 1 to 18
months postoperatively. In a second group of 4 patients an
annuloplasty ring was removed after the repair because of
intractable systolic anterior motion of the mitral valve,
usually due to placement of a small annuloplasty ring.
Subsequently, these patients had a competent valve at the
time of postbypass echocardiogram, but later, because of
annular distortion, became incompetent once again. Since
this experience, we tended to upsize the ring and continued
to be very vigilant on the precise reduction of the height of
the posterior leaflet. The mean ring size for myxomatous
disease is 34 mm. Two of the 4 were re-repaired 4 to 30
months postoperatively by simply placing a larger ring. The
third category of valve failure was new chordal rupture in 5
patients, 4 to 24 months postoperatively. One patient re-
quired rerepaired and the others required valve replacement.
Finally, there was a mixed group of 6 patients in whom
valve failure developed from 1 day to 42 months postoper-
atively because of very advanced valve disease. Two of
these patients had endocarditis and the valve was quite
distorted, while 4 patients had severe generalized Barlow
syndrome involving all 6 areas of the valve. Three of these
patients underwent rerepair, so that 7 of 21 valve failures
were rerepaired at the second operation. There was no
operative mortality at the mitral valve rerepair or replace-
ment surgery.
Discussion
In 1996 several groups began to investigate the possibility
of performing primary valve surgery through much smaller
incisions than heretofore traditionally used, namely, the
complete median sternotomy. Groups at Loma Linda,4, Par-
is,5 and Cleveland6, and somewhat later that year our group
at Brigham,1 began to explore the use of parasternal and/or
ministernotomy incisions for aortic and mitral valve re-
placement and repair. This stimulus came from the increas-
ing use of minimally invasive surgical techniques for all
branches of surgery, the last being cardiac surgery, which
began with minimally invasive coronary bypass surgery in
the 1990s. The small incisions, 6 to 8 cm, were cosmetically
appealing to patients, but the major question was could the
same quality of operation be done through these small
incision and could there be additional benefits, other than
cosmetic, which could be helpful to patient care? Our initial
paper on this subject, presented in 1997,1 investigated a
concomitant group of 50 patients undergoing the same
operation through a median sternotomy and compared them
with our first 50 patients who had minimally invasive
valve surgery, both aortic and mitral. We found that
blood transfusion, hospital stay, and hospital costs were
reduced, but most important, the patients recovered faster
and returned to work more quickly. This study was
TABLE 5. Late follow-up data (N  358)
Mean follow-up 36 mo
Long-term follow-up 5 1.4%
Late deaths 12 3%
Failed repair 21 5.8%
Anterior leaflet disease 6
No ring 4
New chordal rupture 5
Advanced valve disease (Barlow, SBE) 6
Thromboembolism 3 1%
Endocarditis 1 0.3%
SBE, Subacute bacterial endocarditis.
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duplicated 1 year later with 100 patients in each group
with the same conclusions.7
There have been relatively few reports on the medium- and
long-term results after minimally invasive valve operations.8
The data presented here in a 6-year longitudinal study show
that the operative risk is very low, and the vascular, neurologic,
and cardiac complications are also low. Of particular interest is
the low incidence of homologous blood transfusion (24%),
which has been duplicated in other series of minimally inva-
sive valve operations.9,10 We believe the latter is due to the
small incision and the considerably smaller surface area ex-
posed by these incisions. Crossclamp and bypass times have
fallen as a result of increasing volume. The onset of these times
were perhaps 30% to 50% greater than full sternotomy, but are
now no different than open incision time. In addition, these
operations have stimulated the miniaturization of the cardio-
pulmonary bypass circuit with vacuum-assisted venous drain-
age,2 which allows the use of very small cannula for venous
drainage as well as smaller priming volumes for less hemodi-
lution. As these patients do not have coronary artery disease,
this is a low-risk population, but 79 patients (22%) were 70
years of age in this series, none of whom had an operative
death.
The risk of failure of the valve repair, although not
insignificant, is reasonable for the wide variety of valvular
diseases, primarily advanced myxomatous degeneration in-
cluding many patients with bileaflet prolapse and Barlow
syndrome. Figure 2 shows the intraoperative transesopha-
Figure 3. Kaplan-Meier curve of survival following minimally invasive mitral valve repair.
Figure 4. Kaplan-Meier curve of freedom from reoperation following minimally invasive mitral valve repair.
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geal echocardiography score, before and after repair. The
data again demonstrate the importance of placing an annu-
loplasty ring for every mitral valve repair11,12 as approxi-
mately one fourth of the patients who underwent a reopera-
tion had no ring placed at the initial operation even though
the valve was competent at that time. The incidence of
repair failure was 7% in those with anterior leaflet disease
and again documents the fact that anterior leaflet prolapse is
more difficult to treat, which is documented in every series
of mitral valve repairs.13,14 No patient was left with more
than 2MR, but many of these did fall into the reoperation
group due to the causes outlined in Table 5.
Over the 6-year period operative techniques have
changed. Currently, we use a lower ministernotomy and the
standard left atrial approach. No patient had to convert to a
full sternotomy. Other minimally invasive approaches used
and reported on recently with success are the port-access
technique,15 endscopically guided techniques,16 and the ro-
botic assisted mitral valve repair surgery.17 All these studies
similarly show low mortality and good medium-term re-
sults.
The present study documents the safety of minimally
invasive mitral valve repair surgery in 358 patients. The low
incidence of homologous blood utilization and the require-
ment for post–hospital rehabilitation confirms data from
previous studies. We also document that the reparability of
the mitral valve is quite high and the probability of valve
failure after the learning curve is overcome is reasonably
low. We believe this safe and efficacious operation will do
much to lower the threshold for the early referral of patients
undergoing mitral valve surgery.
Limitations of the Study
The major limitation of this study is that it is a retrospective
study. Although all of the cardiac surgery data are collected
from the Brigham Cardiac Surgical database to update the
progress of patients, particularly for valve repair, patients
had to be retrospectively contacted. We had a low rate of
patients lost to follow-up (1.5%). To truly gauge the effec-
tiveness of the operation one would have to do a prospective
randomized study, but we do not think this is feasible.
The second limitation is that we do not have consistent
universal long-term echocardiographic data on every pa-
tient. We have data on approximately 75% of such patients
and the results are quite good.
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Discussion
Dr Scot Merrick (San Francisco, Calif). Anybody who does
mitral valve surgery is well aware of the exceptional contributions
of your group, particularly Dr Cohn, over the past several decades
in the advancement of mitral valve surgery, and I think this paper
is a clear reflection of what you have accomplished.
Mitral valve surgery through small incisions is clearly here to
stay. However, can you do the same techniques through a small
incision that you can through regular incision? Are they safe? Will
you get the same long-term results? I think you have gone a long
way to answer some of these questions.
I do have a couple of questions for you. One relates to patient
selection. Most of your patients were relatively young, had very
little comorbidity, had myxomatous disease and mostly of the
posterior leaflet. How did you determine what type of incision to
make in this group of patients? I notice that you did do 51
procedures through a standard incision. Were there criteria that
you used to select out these patients for a large incision, which
would make you avoid doing a small incision?
Dr Greelish. That is an insightful question. This patient pop-
ulation does represent a younger population with less comorbidity,
but that in general reflects our philosophy at the Brigham. My
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